Umoja Biopharma Announces Oral Presentation of First UB-VV400 In Vivo CAR T Cell Therapy Clinical Data and Four Total Presentations at the 68th ASH Annual Meeting

On November 4, 2026 Umoja Biopharma, Inc. (Umoja), a clinical-stage biotechnology company committed to delivering innovative and potentially curative immunotherapies for patients with cancer and autoimmune diseases, reported that four abstracts have been accepted for presentation at the 68th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition, to be held December 12–15, 2026, at the Ernest N. Morial Convention Center in New Orleans, Louisiana, and virtually.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The accepted abstracts include an oral presentation of clinical data from the investigator-initiated trial of UB-VV400, Umoja’s in vivo CD22-directed CAR T cell therapy candidate for relapsed/refractory (R/R) B-cell malignancies, and a poster presentation of clinical data for UB-VV410, an in vivo CD22-directed CAR T cell therapy candidate for systemic lupus erythematosus (SLE) and lupus nephritis (LN). Umoja will also present trial-in-progress posters for the Phase 1/2 study of UB-VV400 and the Phase 1 study of UB-VV500, an in vivo BCMA x GPRC5D-directed CAR T cell therapy candidate for multiple myeloma.

Details of the Umoja presentations at ASH (Free ASH Whitepaper) 2026 are below.

Oral Presentation

Title: A phase 1, open-label study of UB-VV400 +/- rapamycin in relapsed or refractory (R/R) B-cell malignancies
Date/Time: Sunday, December 13, 2026, 5:30–5:45 p.m. CT
Location: Ernest N. Morial Convention Center, New Orleans Theatre B
Publication Number: 707

Poster Presentation

Title: In vivo CAR T-cell generation and B-cell depletion following UB-VV410 administration in patients with treatment-refractory, active systemic lupus erythematosus (SLE)/lupus nephritis (LN)
Date/Time: Sunday, December 13, 2026, 6:00–8:00 p.m. CT
Location: Ernest N. Morial Convention Center, Hall F
Publication Number: 4174

Poster Presentation (Trial in Progress)

Title: A phase 1/2, open-label, multicenter study of UB-VV400 with rapamycin in relapsed or refractory (R/R) B-cell malignancies
Date/Time: Saturday, December 12, 2026, 5:30–7:30 p.m. CT
Location: Ernest N. Morial Convention Center, Hall F
Publication Number: 2393

Poster Presentation (Trial in Progress)

Title: A phase 1, open-label, multicenter study of UB-VV500 with rapamycin in relapsed or refractory (R/R) multiple myeloma (MM)
Date/Time: Sunday, December 13, 2026, 6:00–8:00 p.m. CT
Location: Ernest N. Morial Convention Center, Hall F
Publication Number: 4168

(Press release, Umoja Biopharma, NOV 4, 2026, View Source [SID1234674252])